PT  - JOURNAL ARTICLE
AU  - Horjus, J.
AU  - Banda, T.
AU  - Heerings, M.
AU  - Hakobjan, M.
AU  - Witte, W. De
AU  - Heersema, D.J.
AU  - Jansen, A.J.
AU  - Strijbis, E.M.M.
AU  - de Jong, B.A.
AU  - Slettenaar, A.E.J.
AU  - Zeinstra, E.M.P.E.
AU  - Hoogervorst, E.L.J.
AU  - Franke, B.
AU  - Kruijer, W.
AU  - Jongen, P.J.
AU  - Visser, L.
AU  - Poelmans, G.
TI  - Whole exome sequencing in multi-incident families identifies novel candidate genes for multiple sclerosis
AID  - 10.1101/2022.02.28.22271609
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.02.28.22271609
4099  - http://medrxiv.org/content/early/2022/03/01/2022.02.28.22271609.short
4100  - http://medrxiv.org/content/early/2022/03/01/2022.02.28.22271609.full
AB  - Multiple sclerosis (MS) is a degenerative disease of the central nervous system in which auto-immunity-induced demyelination occurs. MS is thought to be caused by a complex interplay of environmental and genetic risk factors. While most genetic studies have focused on identifying common genetic variants for MS through genome-wide association studies, the objective of the present study was to identify rare genetic variants contributing to MS susceptibility. We used whole exome sequencing (WES) followed by co-segregation analyses in nine multi-incident families with 2 to 4 affected individuals. WES was performed in 31 family members with and without MS. After applying a suite of selection criteria, co-segregation analyses for a number of rare variants selected from the WES results were performed, adding 24 family members. This approach resulted in 12 exonic rare variants that showed acceptable co-segregation with MS within the nine families, implicating the genes MBP, PLK1, MECP2, MTMR7, TOX3, CPT1A, SORCS1, TRIM66, ITPR3, TTC28, CACNA1F, and PRAM1. Of these, three genes (MBP, MECP2, and CPT1A) have been previously reported as carrying MS-related rare variants. Six additional genes (MTMR7, TOX3, SORCS1, ITPR3, TTC28, and PRAM1) have also been implicated in MS through common genetic variants. The proteins encoded by all twelve genes containing rare variants interact in a molecular framework that points to biological processes involved in (de-/re-)myelination and auto-immunity. Our approach provides clues to possible molecular mechanisms underlying MS that should be further studied in cellular and/or animal models.Competing Interest StatementP.J. Jongen received honoraria from Bayer Netherlands for consulting activities. G. Poelmans is director of Drug Target ID, Ltd. All other authors do not report any conflicts of interest.Funding StatementThis work was supported by the National Multiple Sclerosis Foundation, The Netherlands.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The "Medische Ethische Toetsingscommissie (METC) Brabant" (i.e., the relevant Dutch Medical Ethical Committee) approved this study, and written informed consent was provided by each participant (approved research study number: NL62481.028.17 / P1738).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript